Dr Henri Grech

I graduated from the Royal Free Hospital School of Medicine, University of London, in 1983. I started my specialty training in Haematology having completed my general medicine training rotating through various medical specialties. My specialty training posts included a registrar post in Guildford, a lecturer’s post in Haematology at St Thomas’ Hospital in London and a senior registrar rotation between University of Southampton Hospitals and Royal Bournemouth Hospital.

I was appointed consultant at the Royal Berkshire Hospital in 1995 where I had introduced a multidisciplinary approach to management of patients with Haematological disorders. This included setting up a Clinical Trials Team, now part of the TVCRN funded Trust Trials Team whilst acting as PI for a number of MRC / NCRN-badged clinical trials in acute and chronic leukaemia, lymphoma, myeloma and primary thrombocythemia. I had also collaborated with GSK as local PI in three clinical trials of a new drug (Revolade) for the treatment of ITP, which has since introduced a paradigm shift in the management of patients with this condition. My management roles at various points included Head of Department for Laboratory Haematology, Clinical Director, and Clinical Governance Lead. I had also introduced specialty training posts rotating with Oxford, and as Trust Specialty Tutor I was also a member of the regional Specialty Training Committee. I have also served as examiner for the Royal College of Pathologists until 2020 after having retired from NHS work.

My area of expertise includes the investigation and treatment for anaemia, and other blood count abnormalities, haemochromatosis, bleeding and clotting disorders, chronic leukaemia, low grade lymphoma, chronic bone marrow disorders and myeloma and related disorders.

I have authored a number of case reports, and co-authored in a number of publications covering a number of areas to include leucocyte adhesion in sickle cell disease, norpethidine toxicity during pain control in sickle cell disease, ambulatory management of deep vein thrombosis, management of relapsed / refractory CLL, characterisation of bone marrow biopsy features in LGL Leukaemia, real world experience of the use of thrombopoietin receptor agonists in ITP, and the impact of disease and its treatment on platelet activation as a factor contributing to thrombosis in myeloma and related disorders.